AstraZeneca PLC (AZN.LN) said Wednesday that its asthma treatment drug tralokinumab didn't meet its primary endpoint in a clinical trial.
Tralokinumab didn't demonstrate a significant reduction in the annual rate of asthma attacks in the first of two Phase III clinical trials, the pharmaceutical company said. The results of the second trial are expected in the second half of 2017.
Continue Reading Below
Write to Tapan Panchal at firstname.lastname@example.org
(END) Dow Jones Newswires
May 10, 2017 02:48 ET (06:48 GMT)